Team looks to experimental cancer drug to dampen bronchospasm

December 7, 2016 by Suzanne Leigh

UC San Francisco researchers have developed a new treatment strategy for asthma that acts in a completely different way than standard drugs that have been used for decades as "rescue" medicines.

The new type of drug treatment, which they tested in asthmatic lab mice and in tissue from cadaveric human lungs, appears to have an add-in effect to drug mainstays, like albuterol, and might potentially save lives, according to authors of the study, published online on Dec. 5, 2016, in the Journal of Clinical Investigation.

One in 12 adults has , according to the Centers for Disease Control and Prevention. In 2009, asthma was found to be responsible for close to 500,000 hospitalizations, 1.9 million emergency department visits and 3,388 deaths.

"Our hope is that this will be a new, effective drug treatment strategy for dampening exaggerated airway responsiveness in asthma, even under circumstances in which existing interventions are ineffective," said Aparna Sundaram, MD, an assistant professor of medicine at UCSF and the lead author of the study.

The drug used in the experiments on mice had previously been tested in phase II clinical trials as a way to block blood-vessel growth within tumors. The UCSF researchers have begun working with pharmaceutical scientists on campus to develop more potent drugs.

Sundaram probed the intricacies of a biological mechanism that generates tension during "bronchospasm," the prolonged contraction of the smooth that surrounds lung airways that occurs during an asthma attack, which results in narrowing of the air passages and oxygen deprivation.

Sundaram identified proteins that cause airway muscle cells to stick to the underlying cellular scaffolding and transmit the force generated by muscle contraction, and she found that she could disrupt these attachments and thereby decrease muscle contraction and relieve constriction of the airways.

'Little progress' for therapies that target muscle

The underlying cause of hyper-responsiveness of airway smooth muscle in asthma is an abnormal immune response. Steroid drugs have long been used to quiet the immune system in asthmatics. Newer drugs more specifically target immune responses that underlie the development of asthma. But these drugs act slowly and they do not work for all patients. Faster-acting rescue medicines, such as albuterol, a bronchodilator developed a half-century ago, target the contracting muscle that is the immediate cause of bronchospasm in asthma, allowing constricted airways to expand again. These remain standard treatment for asthma attacks.

"There has been very little progress in terms of therapies that target muscle," Sundaram said. In part, this is because the biological mechanism targeted by standard therapies plays a crucial role in cellular processes throughout the body, and efforts to improve old drug standbys have resulted in experimental drugs that often fail due to intolerable side effects, she said.

These standard therapies affect the movement of muscle filaments that occurs during as a result of the interaction of the proteins actin and myosin, through well-understood mechanisms that have been described in myriad textbooks for generations.

"What is most exciting about this new work is that we showed we can modulate tension transmission in a way that does not depend on modulating actin and myosin," Sundaram said.

Sundaram designed the experiments and wrote the newly published study with senior author Dean Sheppard, MD, professor of medicine and Chief of the Pulmonary, Critical Care, Allergy and Sleep Division at UCSF.

Drug found to enhance airway-relaxing effect of standard treatment

Sundaram homed in on a specific member of a family of molecules known as integrins, a type of cell protein that spans the cell's outer membrane and plays a role in tethering cells to the underlying matrix of scaffolding proteins, but which also engages in bi-directional signaling to reshape this extracellular matrix in response to changing conditions. Just as there are many integrins, there also are a variety of distinct structural proteins that are incorporated within the extracellular matrix.

Through a series of experiments, Sundaram eventually determined that muscle tension in airway smooth muscle was largely determined by the attachment of a specific cellular integrin, called α5β1, to a specific scaffolding protein, called fibronectin.

In experiments on airway tissue from cadaveric human lungs, the UCSF researchers found that disrupting the matrix surrounding cells impaired contraction in response to administration of a type of asthma-inducing "cytokine" molecule that is secreted by immune cells. In addition, when the researchers administered the cancer drug to inhibit α5β1 directly into the airways of mice, it also dampened the airway hyper-responsiveness caused by allergen challenge. Furthermore, using the drug to block α5β1 in mouse trachea also enhanced the airway-relaxing effect of the standard bronchodilator isoproterenol.

"Prevention of asthma through new biologic strategies that target the immune system is important, but regardless of an asthmatic patient's immune system characteristics, the treatment of bronchospasm in asthma will always be required," Sundaram said.

Explore further: Research team learns more about why airway closes up during asthma attacks

More information: Aparna Sundaram et al. Targeting integrin α5β1 ameliorates severe airway hyperresponsiveness in experimental asthma, Journal of Clinical Investigation (2016). DOI: 10.1172/JCI88555

Related Stories

Research team learns more about why airway closes up during asthma attacks

October 16, 2014
The molecular regulation of smooth-muscle contraction is an important determinant of airway responses during an acute asthmatic attack. In acute asthma, various triggers, including viral illnesses and aeroallergens, can cause ...

Studies identify differences underlying the airway responses of patients with asthma

October 5, 2016
More than 300 million people worldwide are affected by asthma, 25 million in the U.S. alone, and for most of them, allergy is an underlying cause. But why do some individuals allergic to airborne allergens develop asthma ...

Researchers discover new pathway that may trigger asthma

April 18, 2016
Asthma is an enormous public health problem that continues to grow larger, in part because scientists don't fully understand how it is caused. Existing therapies don't cure the disease and often don't even significantly alleviate ...

Can you smell through your lungs?

November 3, 2016
It was always thought that olfactory receptors' sole bodily function was to smell, and could only be found inside a nose. But now a new study, published in Frontiers in Physiology, has found two olfactory receptors in human ...

Stop the rogue ADAM gene and you stop asthma

July 21, 2016
Scientists at the University of Southampton have discovered a potential and novel way of preventing asthma at the origin of the disease, a finding that could challenge the current understanding of the condition.

Asthma study provides 'paradigm shift' in understanding of life-threatening condition

October 27, 2016
A new study led by the University of Leicester to understand how to improve the health of severe asthma patients has made a breakthrough finding.

Recommended for you

Targeting 'broken' metabolism in immune cells reduces inflammatory disease

July 12, 2017
The team, led by researchers at Imperial College London, Queen Mary University of London and Ergon Pharmaceuticals, believes the approach could offer new hope in the treatment of inflammatory conditions like arthritis, autoimmune ...

A perturbed skin microbiome can be 'contagious' and promote inflammation, study finds

June 29, 2017
Even in healthy individuals, the skin plays host to a menagerie of bacteria, fungi and viruses. Growing scientific evidence suggests that this lively community, collectively known as the skin microbiome, serves an important ...

Inflammatory bowel disease: Scientists zoom in on genetic culprits

June 28, 2017
Scientists have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease. The team from the Wellcome Trust Sanger Institute and their collaborators ...

Trials show unique stem cells a potential asthma treatment

June 28, 2017
A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

Researchers find piece in inflammatory disease puzzle

May 23, 2017
Inflammation is the process by which the body responds to injury or infection but when this process becomes out of control it can cause disease. Monash Biomedicine Discovery Institute (BDI) researchers, in collaboration with ...

Researchers reveal potential target for the treatment of skin inflammation in eczema and psoriasis

May 22, 2017
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep. Atopic dermatitis, also known as eczema, is primarily driven by an allergic reaction, while psoriasis is considered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.